Skip to main content
placeholder image

First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2021

Citation


  • Roohullah, A., Ganju, V., Zhang, F., Zhang, L., Yu, T., Wilkinson, K., . . . de Souza, P. (2021). First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.. Journal of Clinical Oncology, 39(15_suppl), 2517. doi:10.1200/jco.2021.39.15_suppl.2517

Web Of Science Accession Number


Start Page


  • 2517

End Page


  • 2517

Volume


  • 39

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2021

Citation


  • Roohullah, A., Ganju, V., Zhang, F., Zhang, L., Yu, T., Wilkinson, K., . . . de Souza, P. (2021). First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.. Journal of Clinical Oncology, 39(15_suppl), 2517. doi:10.1200/jco.2021.39.15_suppl.2517

Web Of Science Accession Number


Start Page


  • 2517

End Page


  • 2517

Volume


  • 39

Issue


  • 15_suppl

Place Of Publication